Posted inBiotechnology
Diverse Patients Share Views on Hypertension Care in Safety-Net Settings
Hypertension is one of the most common and most consequential chronic conditions in the United States, yet for millions of…
Posted inBiotechnology
Join4Joy shows promising feasibility for older nursing home residents
Nursing home residents across Spain, France, and Germany did not just tolerate a twelve-week physical activity program—they loved it. A…
Posted inBiotechnology
Astrocyte model of Batten disease reveals mitochondrial and metabolic defects
In a development that could reshape how scientists understand and ultimately treat one of the most devastating childhood neurodegenerative conditions,…
Posted inBiotechnology
MTHFR C677T polymorphism defines metabolic subtypes in polyendocrine metabolic ovarian syndrome
A single genetic variant may help explain why some women with Polyendocrine Metabolic Ovarian Syndrome (PMOS) develop severe metabolic complications…
Posted inBiotechnology
New Polycarbonate Polyurethanes Show Promise for Durable Polymer Mitral Valves
Polymeric heart valves have long promised the best of both worlds in prosthetic cardiology: the durability of mechanical valves and…
Posted inBiotechnology
Galaxamide protects mouse uterus from cisplatin injury via anti-inflammatory effects
A sea-derived molecule best known as a potential anticancer agent may also shield the uterus from one of chemotherapy’s most…
Posted inBiotechnology
Moving NAMs from Progress to Practice: Building the Foundation for Broader Adoption
The future of NAMs depends on more than innovation. Learn how sourcing, standards and evidence can accelerate adoption.
Posted inBiotechnology
Luma locks down 15-year, $410M fund for life science investments
Luma Group announced the final close of its inaugural life sciences venture capital fund totaling $410 million.
Posted inBiotechnology
GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturing
Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up…
Posted inBiotechnology
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start…